SPOTLIGHT -
November 13th 2024
Pharma looks to take advantage of expanded access programs across Asia-Pacific region.
EVERSANA's Ryan discusses the company’s recent expansion into new markets in Europe.
October 29th 2024
The president of compliance services discusses the company’s recent expansion into new markets.
August 20th 2024
In an interview with Pharm Exec Associate Editor Don Tracy, Joseph Mikhael, chief medical officer, IMF, offers a glimpse at multiple initiatives that the IMF is working towards to improve myeloma treatment globally.
August 13th 2024
The region is moving to the forefront in integrating therapeutic innovation.
Eenie, Meenie, Minie, Biominas
Biominas helps foster the development of biotech-related businesses in Brazil.
Hungary Report: Redefining Sustainability
Hungary's high-quality infrsatructure, highly skilled labor force, and central geographic location have turned the country into an attractive destination for investment.
Emerging Markets: Bridging the Cancer Divide
William Looney looks at how Big Pharma is attempting to bridge the emerging markets' widening cancer divide.
Financing R&D Through a Range of Consumer Products
The use and study of DDW by the Hungarian medical community
Capitalizing on Centralization
A quick chat with CMO of Assign Group Dr. Kata Mazalin
Pharma 2012: Hard Times Before the Harvest
The challenge for 2012 is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap.
Here's to a Happier New Year?
A turbulent year is ahead for European pharma, while EFPIA's Director General begins to rethink its approach to new science.
European Pharma to Surge Ahead Of US?
The next two years may see a shake up in the world's current top pharmaceutical companies, with Pfizer likely to be the only US firm to remain in the top five by sales.
Pharm Exec's 2012 Pipeline Report
It's a neck and neck race toward safer, faster, and medically superior treatments. Which organizations have what it takes to jockey their products into the winner's circle?
UK Report: Keep Calm and Carry On ... Differently
Even as the global economic roller coaster affects one of the country's dearest public institutions-the National Health Service-there is still reason for optimism in these times of austerity
The Word on UK Biotech
GM's and investors find consensus in identifying innovation and productivity emerging from academia and small startups
China's Future in Bioscience
Will big investments in infrastructure carry the day in positioning China as a global drug innovation powerhouse?
Europe's Transparency Directive Revisited
The effect on pharma of the EU's Transparency Directive has been overly constraining, but will the mooted revisions offer any room to maneuver?
DW Languages – Rebuilding the UK Word by Word
The pharmaceutical industry in Britain is a key sesctor in the full economic recovery of the country
Was 2011 the End of the Beginning?
The gap in perception is one of industry's biggest problems because it adds ballast to the idea that medicines are just a simple procurement item, writes William Looney.
Does a German Launch Make Sense?
Will the structure and ambiguity of Germany's new medicines pricing system bring a halt to new drug launches in Europe's largest market?
Europe Tackles 'Advertising in Disguise' Fears
The EC's latest proposals have thrown water on Europe's firey Direct-to-Consumer advertising debate. But is it enough to keep the flames at bay?
Strategic Acquisition: A CEO's View
Richard Pops, Chief Executive Officer of Alkermes, explains how the company has established itself as a global, Irish-based firm.
GxP Cloud — Business Enablement for Life Sciences
GxP Cloud - business enablement for Life Sciences
Y. K Hamied : Changing the Dialogue
Y.K. Hamied, PhD, Chairman, Cipla
Emerging Markets:The Myths and Traps
Success in the emerging markets depends significantly on navigating the myths and mental traps.
Sir Michael Rawlins: Regulation and Reputation
Sir Michael Rawlins, Chairman of the UK National Institute for Health and Clinical Excellence
Sweden: Setting the Pace for Global Pharma
Garbo gets it ...
Strategic Outsourcing — The Road to Cost Efficiencies and Increased Productivity in Clinical Development
Big Pharma has increasingly turned to strategic outsourcing models to realize their own enterprise-wide strategic goals. Small- and medium-sized companies need to follow suit.
The Power of Product Development Partnership
Can cooperative ties between Big Pharma, NGOs, government, and international organizations pay the freight in making the fight against neglected diseases a permanent fix in global health?
Front and Center in the Fight against TB
Pharm Exec talks to Dr. Mel Spigelman, President and CEO of the TB Alliance, about the organization's tuberculosis priorities.
How to Recruit 70,000 People in One Year
Tata Consultancy Services has grown into one of the largest IT solutions providers in the world
Innovating Around Innovation
Richard Barker, former Director General of ABPI, proposes a new agenda on how to restore public confidence in the value behind science.
India: Good Endings, Good Beginnings!
Within an industry that traditionally moves at a slow pace, the rapidly changing playing field as required both Indian pharmaceutical companies, as well as MNCs, to adjust their strategies accordingly
Should the US Gamble with Risk Sharing?
Especially when payers come to the table holding the best cards - leaving industry second-guessing its strategy.